In inflammatory myopathies, dropped head/bent spine syndrome is associated with scleromyositis: an international case–control study

Archive ouverte

Pijnenburg, Luc | Giannini, Margherita | Bouchard-Marmen, Maude | Arnaud, Laurent | Barsotti, Simone | Bellando-Randone, Silvia | Bernardi, Livio | Bini, Paola | Blagojevic, Jelena | Codullo, Veronica | Couderc, Marion | de Moreuil, Claire | Dernis, Emanuelle | Diamanti, Luca | Dubost, Jean, Jacques | Duval, Fanny | Emmi, Giacomo | Galempoix, Jean-Marc | Geny, Bernard | Gottenberg, Jacques-Eric | Groza, Monica | Guffroy, Aurelien | Guichard, Isabelle | Guilpain, Philippe | Hervier, Baptiste | Hudson, Marie | Iaccarino, Luca | Iannone, Florenzo | Lebrun, Delphine | Marchioni, Enrico | Mariampillai, Kuberaka | Maurier, Francois | Mosca, Marta | Nadaj-Pakleza, Aleksandra | Nannini, Carlotta | Piot, Jean-Maxime | Prieto-González, Sergio | Poursac, Nicolas | Rouanet, Eglantine | Sellam, Jérémie | Selva-O'Callaghan, Albert | Séverac, François | Sibilia, Jean | Sole, Guilhem | Soulages, Antoine | Terrier, Benjamin | Tournadre, Anne | Troyanov, Yves | Vernier, Nathalie | Vesperini, Veronique | Viallard, Jean-François | Ziane, Rahima | Cavagna, Lorenzo | Meyer, Alain

Edité par CCSD ; BMJ Publishing Group -

International audience. Background: Some myopathies can lead to dropped head or bent spine syndrome (DH/BS). The significance of this symptom has not been studied in inflammatory myopathies (IM).Objectives: To assess the significance of DH/BS in patients with IM.Methods: Practitioners from five IM networks were invited to report patients with IM suffering from DH/BS (without other known cause than IM). IM patients without DH/BS, randomly selected in each participating centre, were included as controls at a ratio of 2 to 1.Results: 49 DH/BS-IM patients (DH: 57.1%, BS: 42.9%) were compared with 98 control-IM patients. DH/BS-IM patients were older (65 years vs 53 years, p<0.0001) and the diagnosis of IM was delayed (6 months vs 3 months, p=0.009). Weakness prevailing in the upper limbs (42.9% vs 15.3%), dysphagia (57.1% vs 25.5%), muscle atrophy (65.3% vs 34.7%), weight loss (61.2% vs 23.5%) and loss of the ability to walk (24.5% vs 5.1%) were hallmarks of DH/BS-IM (p≤0.0005), for which the patients more frequently received intravenous immunoglobulins (65.3% vs 34.7%, p=0.0004). Moreover, DH/BS-IM patients frequently featured signs and/or complications of systemic sclerosis (SSc), fulfilling the American College of Rheumatology/European Alliance of Associations for Rheumatology criteria for this disease in 40.8% of the cases (vs 5.1%, p<0.0001). Distribution of the myopathy, its severity and its association with SSc were independently associated with DH/BS (p<0.05). Mortality was higher in the DH/BS-IM patients and loss of walking ability was independently associated with survival (p<0.05).Conclusion: In IM patients, DH/BS is a marker of severity and is associated with SSc (scleromyositis).

Suggestions

Du même auteur

Granulomatosis-associated myositis

Archive ouverte | Dieudonné, Yannick | CCSD

International audience. Objective To refine the predictive significance of muscle granuloma in patients with myositis. Methods A group of 23 patients with myositis and granuloma on muscle biopsy (granuloma-myositis)...

Agreement between local and central anti-synthetase antibodies detection: results from the Classification Criteria of Anti-Synthetase Syndrome project biobank.

Archive ouverte | Loganathan, Aravinthan | CCSD

OBJECTIVES: The CLASS (Classification Criteria of Anti-Synthetase Syndrome) project is a large international multicentre study that aims to create the first data-driven anti-synthetase syndrome (ASSD) classification criteria. Iden...

COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

Archive ouverte | Avouac, Jérôme | CCSD

International audience. Background: Various observations have suggested that the course of COVID-19 might be less favourable in patients with inflammatory rheumatic and musculoskeletal diseases receiving rituximab c...

Chargement des enrichissements...